Sign In
Buy CYDY
$0.276
-0.0143 (-4.93%)
At Close: Jun 03, 2026
CytoDyn: Preparing For Capitulation After A Successful Failure
08:34am, Friday, 12'th Mar 2021
CytoDyn: Preparing For Capitulation After A Successful Failure
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CytoDyn Inc. - CYDY
05:40am, Friday, 12'th Mar 2021
NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CytoDyn Inc. ("CytoDyn" or the "Company") (OTCMKTS: CYDY). Such investors are advised to c
CytoDyn says 20 patients enrolled and dosed so far in Vyrologix trial in coronavirus long-haulers
08:57am, Thursday, 11'th Mar 2021
CytoDyn Inc (OTCQB:CYDY) announced Thursday that 20 patients have been enrolled and dosed in the first 10 days of its Phase 2 trial of its drug Vyrologix (leronlimab-PRO 140) as a treatment for COVID-
CytoDyn's Long-Haulers COVID-19 Trial Enrolled 20 Patients Within 10 Days; Enrollment to be Completed This Month
03:34am, Thursday, 11'th Mar 2021
VANCOUVER, Washington, March 11, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 14
CytoDyn Inc (OTCQB:CYDY) said a Phase III trial of its leronlimab treatment, known as Vyrologix, for severe-to-critical patients with coronavirus (COVID-19) has demonstrated continued safety, a substa
CytoDyn to Release CD12 Trial Detailed Results via Form 8-K After Investment Community Webcast, Monday, March 8
06:10am, Monday, 08'th Mar 2021
These trial results are currently being prepared to be submitted for publication
CytoDyn to File Accelerated Rolling Review with MHRA and Interim Order (IO) with Health Canada for COVID-19
06:05am, Monday, 08'th Mar 2021
U.S. FDA Reviewing Protocol for More COVID-19 Critical Patients to be Enrolled to Support Potential EUA
VANCOUVER, Washington, March 08, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 14
CytoDyn to File Accelerated Rolling Review with MHRA and Interim Order (IO) with Health Canada for COVID-19
08:40pm, Saturday, 06'th Mar 2021
U.S. FDA Reviewing Protocol for More COVID-19 Critical Patients to be Enrolled to Support Potential EUA
VANCOUVER, Washington, March 05, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 14
VANCOUVER, Washington, March 05, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 14
CytoDyn Files Form S-3 to Replace Expiring Shelf Registration Statement
05:27pm, Wednesday, 03'rd Mar 2021
VANCOUVER, Washington, March 03, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 14
7 Biotech Stocks Focused on Chronic Covid Treatment
01:30pm, Monday, 22'nd Feb 2021
Keep in mind downside risk, if their respective candidates fail to pan out. But, there may be opportunity with these seven biotech stocks targeting treatments for long-haul Covid-19.
CytoDyn says data from its Phase 2b/3 Vyrologix coronavirus trial will be made public, pending regulatory talks
08:59am, Monday, 22'nd Feb 2021
CytoDyn Inc (OTCQB:CYDY) announced Monday that study results have been unblinded from the CD12 trial of its drug Vyrologix (leronlimab or PRO-140) in coronavirus (COVID-19) patients, and the company w
CytoDyn expects to release CD12 data and complete discussions with various regulatory agencies within 2 to 3 weeks
